Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesQualitative or Semiquantitative ImmunoassaysCPT cpt-86300-ca-15-3-ca-27-29-tumor-marker-assay
    Ask Trek AI about this page

    CPT 86300: Quantitative Serum Test for CA 15-3/CA 27.29

    CPT code 86300 describes a quantitative laboratory immunoassay that measures serum levels of the tumor antigen CA 15-3 and the related marker CA 27.29, used as breast cancer tumor markers; the service is a quantitative tumor marker test typically performed in a clinical laboratory or hospital laboratory setting on a patient’s serum sample.

    For related coverage guidance, see recent payer policy updates: Allergen Subcutaneous Immunotherapy (SCIT), Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policy, Allergy and Sensitivity Tests of Uncertain Efficacy.

    Customize your policy alerts

    Sign up for cpt 86300 policy alerts

    Get alerted when payer policies referencing 86300 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 54-year-old woman with a history of treated stage II invasive ductal carcinoma of the breast presents for routine oncologic surveillance. She has completed surgery and adjuvant therapy and attends periodic follow-up to monitor for recurrence. Her oncologist orders a serum tumor marker panel including measurement of CA 15-3/CA 27.29 to assess trends over time. A phlebotomy draw is performed in the outpatient laboratory; the specimen is processed by the clinical laboratory scientist who runs a quantitative immunoassay for CA 15-3/CA 27.29. Results are reported to the ordering provider and placed in the electronic medical record; significant rises from prior values prompt clinical correlation and potential imaging or additional testing. Typical site of service is an outpatient hospital laboratory or independent clinical laboratory associated with an oncology clinic.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81002Urinalysis, non-automated, without microscopyOften performed in outpatient visits alongside lab panels for general assessment.
    36415Collection of venous blood by venipunctureSpecimen collection procedure required prior to performing the CA 15-3/CA 27.29 assay.
    86301Antigen; tumor-associated, quantitative, other (e.g., CA 19-9)Other tumor marker immunoassays that may be ordered concurrently for oncologic surveillance.
    88305Level IV surgical pathology, gross and microscopic examinationPerformed when tissue biopsy or recurrence is being evaluated after abnormal tumor marker trends.

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    76Modifier -76, Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional, is appended when the same provider performs an identical, medically necessary procedure or…- Use modifier -76 when the same physician or other qualified health care professional performs an identical procedure or service a second (or subsequent) time on the same date of service and the…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    208000000X
    207L00000X
    103TE1100X
    1744P3200X
    103TS0200X
    374T00000X
    363LG0600X
    261Q00000X

    Related ICD-10-CM Codes

    27 rows

    ICD-10-CM CodeDescription
    C50.111Malignant neoplasm of central portion of right female breast
    C50.112Malignant neoplasm of central portion of left female breast
    C50.121Malignant neoplasm of central portion of right male breast
    C50.122Malignant neoplasm of central portion of left male breast
    C50.211Malignant neoplasm of upper-inner quadrant of right female breast
    C50.212Malignant neoplasm of upper-inner quadrant of left female breast
    C50.311Malignant neoplasm of lower-inner quadrant of right female breast
    C50.312Malignant neoplasm of lower-inner quadrant of left female breast
    C50.411Malignant neoplasm of upper-outer quadrant of right female breast
    C50.412Malignant neoplasm of upper-outer quadrant of left female breast

    Showing 1–10 of 27

    Related Payer Policy Updates

    Specialty: Allergy/Clinical Immunology1 / 3

    10 rows

    PolicyPayerEffective Date
    Allergen Subcutaneous Immunotherapy (SCIT)Providence Health Plan2026-11-01
    Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policybcbsvermont2026-11-01
    Allergy and Sensitivity Tests of Uncertain Efficacyregence2026-10-01
    Allergy Testing and InjectionsUnitedHealthcare2026-10-01
    Allergy TestingProvidence Health Plan2026-10-01
    Diagnosis of Idiopathic Environmental IntoleranceOscar Health2026-10-01
    Allergen Testingblue cross blue shield - louisiana2026-09-15
    Allergen TestingBlue Cross Blue Shield - New Mexico2026-09-04
    Allergen Immunotherapymarylandphysicianscarempc2026-09-01
    ALLERGY TESTING / IMMUNOTHERAPYpriority_health_medicare2026-09-01

    Related Codes

    86803-QUALITATIVE-OR-SEMIQUANTITATIVE-IMMUNOASSAYS-HEPATITIS-C

    CPT 86803: Hepatitis C Antibody Immunoassay in Serum

    CPT-86000-FEBRILE-AGGLUTININS-SEROLOGIC-TEST

    CPT 86000: Febrile Agglutinins (Serologic Agglutination) Test

    CPT-86001-ALLERGEN-SPECIFIC-IGG-LABORATORY-TEST

    CPT 86001: Allergen-Specific IgG Assay, Technical Component

    CPT-86003-ALLERGEN-SPECIFIC-IGE-ASSAY-TECHNICAL

    CPT 86003: Allergen‑Specific IgE Assay Using Crude Allergen Extract

    CPT-86005-MULTI-ALLERGEN-IGE-SCREENING-QUALITATIVE

    CPT 86005: Multi-Allergen Allergen-Specific IgE Screening

    CPT-86008-ALLERGEN-COMPONENT-SPECIFIC-IGE-ASSAY

    CPT 86008: Allergen Component–Specific IgE Assay

    CPT-86015-ANTI-ACTIN-SMOOTH-MUSCLE-ANTIBODY-ASMA

    CPT 86015: Actin (Smooth Muscle) Antibody (ASMA) Immunoassay

    CPT-86021-LEUKOCYTE-ANTIBODY-IDENTIFICATION-LAB-TECHNICAL

    CPT 86021: Leukocyte Antibody Identification Laboratory Test

    CPT-86022-PLATELET-ANTIBODY-IDENTIFICATION-TECHNICAL-TEST

    CPT 86022: Platelet Antibody Detection and Identification

    CPT-86023-PLATELET-ASSOCIATED-IMMUNOGLOBULIN-DETECTION

    CPT 86023: Platelet-Associated Immunoglobulin Assay

    Showing 1–10 of 199

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.